Tyrosine kinase inhibitors response evaluation in phylladelphia positive chronic myeloginous leukemia patients from january 2009 to january 2014 : A retrospective study /
Ibraheem Hassan Kabeel
Tyrosine kinase inhibitors response evaluation in phylladelphia positive chronic myeloginous leukemia patients from january 2009 to january 2014 : A retrospective study / دراسة استعادية لتقييم تأثير الأدوية المثبطة لانزيم التايروزين كاينيز في حالات سرطان لدم الميلودي المزمن موجبة كروموزوم فيلاديلفيا Ibraheem Hassan Kabeel ; Supervised Emad Hamada , Mostafa Elhaddad , Moustafa Aldaly - Cairo : Ibraheem Hassan Kabeel , 2015 - 131 P. : charts ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology (Radiation)
The cause of chronic myeloid leukemia is a constitutively active BCR-ABL tyrosine kinase enzyme. Imatinib,Dasatinib and Nilotinib inhibit this kinase .We analyzed the results of response in patients of ph+ve CML who attended Kasr El Aini center of radiation oncology during the period Jan.2009 to Jan 2014 .We analyzed hematologic and molecular response, together with progression free survival and adverse events.Imatinib induced a hematological response in almost all cases, but its molecular response was less. Dasatinib and Nilotinib were used as a second line after Imatinib failure, suboptimal response, or intolerable adverse effects
CML Dasatinib Imatinib
Tyrosine kinase inhibitors response evaluation in phylladelphia positive chronic myeloginous leukemia patients from january 2009 to january 2014 : A retrospective study / دراسة استعادية لتقييم تأثير الأدوية المثبطة لانزيم التايروزين كاينيز في حالات سرطان لدم الميلودي المزمن موجبة كروموزوم فيلاديلفيا Ibraheem Hassan Kabeel ; Supervised Emad Hamada , Mostafa Elhaddad , Moustafa Aldaly - Cairo : Ibraheem Hassan Kabeel , 2015 - 131 P. : charts ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology (Radiation)
The cause of chronic myeloid leukemia is a constitutively active BCR-ABL tyrosine kinase enzyme. Imatinib,Dasatinib and Nilotinib inhibit this kinase .We analyzed the results of response in patients of ph+ve CML who attended Kasr El Aini center of radiation oncology during the period Jan.2009 to Jan 2014 .We analyzed hematologic and molecular response, together with progression free survival and adverse events.Imatinib induced a hematological response in almost all cases, but its molecular response was less. Dasatinib and Nilotinib were used as a second line after Imatinib failure, suboptimal response, or intolerable adverse effects
CML Dasatinib Imatinib